Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25095994 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1CYP2C9TSHRCYP2C19 | |
| SCHEMBL23583498 | 0.92 | KDM4E (0.39) | KDM4EALDH1A1CYP2C9TSHRCYP2C19 | |
| SCHEMBL24221084 | 0.92 | KDM4E (0.39) | KDM4EALDH1A1CYP2C9TSHRCYP2C19 | |
| SCHEMBL3034291 | 0.88 | — | — | |
| SCHEMBL20310130 | 0.88 | — | — | |
| SCHEMBL27427035 | 0.88 | — | — | |
| SCHEMBL22393984 | 0.88 | — | — | |
| SCHEMBL19014402 | 0.88 | — | — | |
| SCHEMBL15014646 | 0.88 | — | — | |
| SCHEMBL12807885 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230192655-A1 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11502257-B2 | Organic electroluminescence device and amine compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-11-15 | — | — | US | disclosed |
| WO-2022161416-A1 | AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220009894-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-01-13 | — | — | US | disclosed |
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190097157-A1 | POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-10011627-B2 | C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof | YOUNGENE THERAPEUTICS CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-8980912-B2 | Cyclic amine compound and acaricide | NIPPON SODA CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-04-04 | — | — | US | disclosed |
| US-20120309964-A1 | CYCLIC AMINE COMPOUND AND ACARICIDE | NIPPON SODA CO., LTD | 2012-12-06 | — | — | US | disclosed |
| WO-2012010704-A1 | NEW AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
| WO-2007072506-A2 | POLYMORPHIC FORMS OF DOLASETRON MESYLATE AND PROCESSES THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | FGFR4, FGFR1, FGFR2 | KDM4E 963/4885ALDH1A1 523/4885CYP2C9 924/4885 |
| US-10011627-B2 | C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof | SLC5A1, SLC5A2, UGGT1 | KDM4E 2821/4885ALDH1A1 965/4885CYP2C9 194/4885 |
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | FGFR4, FGFR1, FGFR2 | KDM4E 1217/4885ALDH1A1 855/4885CYP2C9 425/4885 |
| US-20120309964-A1 | CYCLIC AMINE COMPOUND AND ACARICIDE | CYCS, NAT10, CYC1 | KDM4E 2666/4885ALDH1A1 1162/4885CYP2C9 1354/4885 |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | KDM4E 664/4885ALDH1A1 3835/4885CYP2C9 4476/4885 |
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | KDM4E 2530/4885ALDH1A1 4181/4885CYP2C9 4709/4885 |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | FGFR4, FGFR1, FGFR3 | KDM4E 355/4885ALDH1A1 1304/4885CYP2C9 2072/4885 |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | KDM4E 4511/4885ALDH1A1 2488/4885CYP2C9 452/4885 |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | KDM4E 2789/4885ALDH1A1 3474/4885CYP2C9 4850/4885 |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | FGFR4, FGFR1, FGFR2 | KDM4E 1217/4885ALDH1A1 855/4885CYP2C9 425/4885 |
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP4K2 | KDM4E 938/4885ALDH1A1 1088/4885CYP2C9 2495/4885 |
| US-20230192655-A1 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK1, IRAK2 | KDM4E 686/4885ALDH1A1 2337/4885CYP2C9 1275/4885 |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | KDM4E 3871/4885ALDH1A1 1516/4885CYP2C9 375/4885 |
| US-20220009894-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORA, RORB, RORC | KDM4E 1636/4885ALDH1A1 248/4885CYP2C9 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.